PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma

Journal of Pathology

Volumn 208, Issue 5, 2006, Pages 615-623

  Lagonigro, M S ^a   Tamborini, E ^a   Negri, T ^a   Staurengo, S ^a   Dagrada, G P ^a   Miselli, F ^a   Gabanti, E ^a   Greco, A ^a   Casali, P G ^a   Pierotti, M A ^a,b   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

Author keywords

Conventional central primary chondrosarcoma; KIT; Molecular targets; PDGFR ; PDGFR

Indexed keywords

COMPLEMENTARY DNA; GENE PRODUCT; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR; LIGAND; STEM CELL FACTOR RECEPTOR; TUMOR PROTEIN;

ARTICLE; AUTOCRINE EFFECT; BIOCHEMISTRY; CHONDROSARCOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCREENING; WESTERN BLOTTING; BONE TUMOR; ENZYME IMMUNOASSAY; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; METHODOLOGY; PHOSPHORYLATION;

BONE NEOPLASMS; CHONDROSARCOMA; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; LIGANDS; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33645231467     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1945     Document Type: Article

References (34)

1. Bergh P, Gunterberg B, Meis-Kindblom JM, Kindblom LG. Prognostic factors and outcome of pelvic, sacral and spinal chondrosarcomas: a center-based study of 69 cases. Cancer 2001;91(7):1201-1212.
2. Reith JD, Horodyski MB, Scarborough MT. Grade 2 chondrosarcoma: stage I or stage II tumor? Clin Orthop Relat Res 2003;415:45-51.
3. Bovee JV, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC. Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. Lancet Oncol 2005;6(8):599-607 [review].
4. Jagasia AA, Block JA, Qureshi A, Diaz MO, Nobori T, Gitelis S, Iyer AP. Chromosome 9 related aberrations and deletions of the CDKN2 and MTS2 putative tumor suppressor genes in human chondrosarcomas. Cancer Lett 1996;105(1):91-103.
5. Asp J, Sangiorgi L, Inerot SE, Lindahl A, Molendini L, Benassi MS, Picci P. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Int J Cancer 2000;85(6):782-786.
6. van Beerendonk HM, Rozeman LB, Taminiau AH, Sciot R, Bovee JV, Cleton-Jansen AM, Hogendoorn PC. Molecular analysis of the INK4A/INK4A-ARF gene locus in conventional (central) chondrosarcomas and enchondromas: indication of an important gene for tumour progression. J Pathol 2004;202(3):359-366.
7. Blasenbreu S, Baretton GB, Bender C, Haas CJ, Diebold J, Lohrs U. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression]. Verh Dtsch Ges Pathol 1998;82:284-289 [in German].
8. Yamaguchi T, Toguchida J, Wadayama B, Kanoe H, Nakayama T, Ishizaki K, et al. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas. Anticancer Res 1996;16(4A):2009-2015.
9. Lin C, Meitner PA, Terek RM. PTEN mutation is rare in chondrosarcoma. Diagn Mol Pathol. 2002;11(1):22-26.
10. Sulzbacher I, Birner P, Trieb K, Muhlbauer M, Lang S, Chott A. Platelet-derived growth factor-alpha receptor expression supports the growth of conventional chondrosarcoma and is associated with adverse outcome. Am J Surg Pathol 2001;25(12):1520-1527.
11. Bertoni F, Bacchini P, Hogendoorn PCW. Chondrosarcoma. In World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone, Fletcher CDM, Unni KK, Mertens F (eds). IARC Press: Lyon, 2002; 247-251.
12. Fechner RE, Mills SE. Tumors of Bones and Joints. Atlas of Tumor Pathology, 3rd series, Fascicle 8. Armed Forces Institute of Pathology: Washington, DC, 1993.
13. Evans HL, Ayala AG, Romsdahl MM. Prognostic factors in chondrosarcoma of bone. A clinicopathologic analysis with emphasis on histologic grading. Cancer 1977;40:818-831.
14. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, et al. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations. Cancer 2005;104(1):159-169.
15. Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, et al. Imatinib mesylate in chordoma. Cancer 2004;101(9):2086-2097.
16. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 2005;23(4):866-873.
17. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A, et al. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology 2004;127(1):294-299.
18. Tamborini E, Bonadiman L, Negri T, Greco A, Staurengo S, Bidoli P, et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 2004;10(24):8214-8219.
19. Basciani S, Mariani S, Arizzi M, Ulisse S, Rucci N, Jannini EA, et al. Expression of platelet-derived growth factor-A (PDGF-A), PDGF-B, and PDGF receptor-alpha and -beta during human testicular development and disease. J Clin Endocrinol Metab 2002;87(5):2310-2319.
20. Tamborini E, Bonadiman L, Greco A, Gronchi A, Riva C, Bertulli R, et al. Expression of ligand-activated KIT and platelet-derived growth factor receptor beta tyrosine kinase receptors in synovial sarcoma. Clin Cancer Res 2004;10(3):938-943.
21. Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson LC, Franssila K, et al. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol 2005;23(1):49-57; Epub 2004 Nov 15.
22. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79(4):1283-1316 [review].
23. Rozeman LB, Hameetman L, van Wezel T, Taminiau AH, Cleton-Jansen AM, Hogendoorn PC, Bovee JV. cDNA expression profiling of chondrosarcomas: Ollier disease resembles solitary tumours and alteration in genes coding for components of energy metabolism occurs with increasing grade. J Pathol 2005;207(1):61-71.
24. Rosenkranz S, Kazlauskas A. Evidence for distinct signaling properties and biological responses induced by the PDGF receptor alpha and beta subtypes. Growth Factors 1999;16(3):201-216. Review.
25. Nagineni CN, Kutty V, Detrick B, Hooks JJ. Expression of PDGF and their receptors in human retinal pigment epithelial cells and fibroblasts: regulation by TGF-β. J Cell Physiol 2005;203(1):35-43.
26. Rozeman LB, Hameetman L, Cleton-Jansen AM, Taminiau AH, Hogendoorn PC, Bovee JV. Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. J Pathol 2005;205(4):476-482.
27. Yu J, Deuel TF, Kim HR. Platelet-derived growth factor (PDGF) receptor-alpha activates c-Jun NH2-terminal kinase-1 and antagonizes PDGF receptor-beta-induced phenotypic transformation. J Biol Chem 2000;275(25):19076-19082.
28. Klinghoffer RA, Mueting-Nelsen PF, Faerman A, Sham M, Soriano P. The two PDGF receptors maintain conserved signaling in vivo despite divergent embryological functions. Mol Cell 2001;7(2):343-354.
29. Plattner R, Koleske AJ, Kazlauskas A, Pendergast AM. Bidirectional signaling links the Abelson kinases to the platelet-derived growth factor receptor. Mol Cell Biol 2004;24(6):2573-2583.
30. McGary EC, Weber K, Mills L, Doucet M, Lewis V, Lev DC, et al. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clin Cancer Res 2002;8(11):3584-3591.
31. Hofer MD, Fecko A, Shen R, Setlur SR, Pienta KG, Tomlins SA, et al. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors. Neoplasia 2004;6(5):503-512.
32. Kim R, Emi M, Arihiro K, Tanabe K, Uchida Y, Toge T. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer 2005;103(9):1800-1809.
33. Verin AD. Tyrosine phosphorylation and endothelial cell barrier regulation. Am J Pathol 2005;166(4):955-957.
34. Pietras K. Increasing tumor uptake of anticancer drugs with imatinib. Semin Oncol 2004;31(2(suppl 6)):18-23.